These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 35322226

  • 21. Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis.
    Niemietz C, Chandhok G, Schmidt H.
    Molecules; 2015 Sep 30; 20(10):17944-75. PubMed ID: 26437390
    [Abstract] [Full Text] [Related]

  • 22. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy.
    Benson MD, Dasgupta NR, Rissing SM, Smith J, Feigenbaum H.
    Amyloid; 2017 Dec 30; 24(4):219-225. PubMed ID: 28906150
    [Abstract] [Full Text] [Related]

  • 23. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I.
    Clin Auton Res; 2019 Sep 30; 29(Suppl 1):11-17. PubMed ID: 31399774
    [Abstract] [Full Text] [Related]

  • 24. Evolving landscape in the management of transthyretin amyloidosis.
    Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB.
    Ann Med; 2015 Sep 30; 47(8):625-38. PubMed ID: 26611723
    [Abstract] [Full Text] [Related]

  • 25. Cardiac Amyloidosis Treatment.
    Stern LK, Patel J.
    Methodist Debakey Cardiovasc J; 2022 Sep 30; 18(2):59-72. PubMed ID: 35414852
    [Abstract] [Full Text] [Related]

  • 26. Cardiac Amyloidosis Due to Transthyretin Protein: A Review.
    Ruberg FL, Maurer MS.
    JAMA; 2024 Mar 05; 331(9):778-791. PubMed ID: 38441582
    [Abstract] [Full Text] [Related]

  • 27. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
    Porcari A, Razvi Y, Masi A, Patel R, Ioannou A, Rauf MU, Hutt DF, Rowczenio D, Gilbertson J, Martinez-Naharro A, Venneri L, Whelan C, Lachmann H, Wechalekar A, Quarta CC, Merlo M, Sinagra G, Hawkins PN, Fontana M, Gillmore JD.
    Eur J Heart Fail; 2023 Apr 05; 25(4):515-524. PubMed ID: 36644836
    [Abstract] [Full Text] [Related]

  • 28. Targeting transthyretin - Mechanism-based treatment approaches and future perspectives in hereditary amyloidosis.
    Dohrn MF, Ihne S, Hegenbart U, Medina J, Züchner SL, Coelho T, Hahn K.
    J Neurochem; 2021 Mar 05; 156(6):802-818. PubMed ID: 33155274
    [Abstract] [Full Text] [Related]

  • 29. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy.
    Ackermann EJ, Guo S, Booten S, Alvarado L, Benson M, Hughes S, Monia BP.
    Amyloid; 2012 Jun 05; 19 Suppl 1():43-4. PubMed ID: 22494066
    [Abstract] [Full Text] [Related]

  • 30. Developing Therapy for Transthyretin Amyloidosis.
    Campbell CM, Zhang K, Lenihan DJ, Witteles R.
    Am J Med; 2022 Apr 05; 135 Suppl 1():S44-S48. PubMed ID: 35077703
    [Abstract] [Full Text] [Related]

  • 31. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
    Klaassen SHC, Lemmink HH, Bijzet J, Glaudemans AWJM, Bos R, Plattel W, van den Berg MP, Slart RHJA, Nienhuis HLA, van Veldhuisen DJ, Hazenberg BPC.
    Cardiovasc Pathol; 2017 Apr 05; 29():19-22. PubMed ID: 28460244
    [Abstract] [Full Text] [Related]

  • 32. Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.
    Nie T, Heo YA, Shirley M.
    Drugs; 2023 Oct 05; 83(15):1425-1432. PubMed ID: 37728865
    [Abstract] [Full Text] [Related]

  • 33. TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients.
    Moshe-Lilie O, Dimitrova D, Heitner SB, Brannagan TH, Zivkovic S, Hanna M, Masri A, Polydefkis M, Berk JL, Gertz MA, Karam C.
    Amyloid; 2020 Dec 05; 27(4):250-253. PubMed ID: 32578459
    [Abstract] [Full Text] [Related]

  • 34. Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy.
    Campbell CM, Baiyee CAMT, Almaani S, Bumma N, Sharma N, LoRusso S, Redder E, Bittengle J, Pfund K, Friemer M, Tong M, Kahwash R, Efebera Y, Parikh S, Vallakati A.
    Am J Ther; 2020 Dec 05; 30(5):e447-e453. PubMed ID: 37713689
    [Abstract] [Full Text] [Related]

  • 35. The revolution of ATTR amyloidosis in cardiology: certainties, gray zones and perspectives.
    Rapezzi C, Vergaro G, Emdin M, Fabbri G, Cantone A, Sanguettoli F, Aimo A.
    Minerva Cardiol Angiol; 2022 Apr 05; 70(2):248-257. PubMed ID: 35412035
    [Abstract] [Full Text] [Related]

  • 36. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
    Ackermann EJ, Guo S, Benson MD, Booten S, Freier S, Hughes SG, Kim TW, Jesse Kwoh T, Matson J, Norris D, Yu R, Watt A, Monia BP.
    Amyloid; 2016 Sep 05; 23(3):148-157. PubMed ID: 27355239
    [Abstract] [Full Text] [Related]

  • 37. A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Olatunji G, Kokori E, Abraham IC, Omoworare O, Olatunji D, Ezeano C, Emmanuel Adeoba B, Stanley AC, Oluwatobiloba AM, Oluwademilade OB, Shimelis KM, Olanisa O, Aderinto N.
    Medicine (Baltimore); 2024 Jun 28; 103(26):e38767. PubMed ID: 38941378
    [Abstract] [Full Text] [Related]

  • 38. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA, Scheinberg M, Waddington-Cruz M, Heitner SB, Karam C, Drachman B, Khella S, Whelan C, Obici L.
    Expert Rev Clin Pharmacol; 2019 Aug 28; 12(8):701-711. PubMed ID: 31268366
    [Abstract] [Full Text] [Related]

  • 39. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
    Brown EE, Lee YZJ, Halushka MK, Steenbergen C, Johnson NM, Almansa J, Tedford RJ, Cingolani O, Russell SD, Sharma K, Judge DP.
    Amyloid; 2017 Jun 28; 24(2):92-95. PubMed ID: 28494620
    [Abstract] [Full Text] [Related]

  • 40. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy.
    Coelho T, Marques W, Dasgupta NR, Chao CC, Parman Y, França MC, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M, NEURO-TTRansform Investigators.
    JAMA; 2023 Oct 17; 330(15):1448-1458. PubMed ID: 37768671
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.